Clinical Scorecard: FDA Rejection for Low-Dose Atropine Formulation
At a Glance
| Category | Detail |
|---|---|
| Condition | Pediatric Progressive Myopia (PPM) |
| Key Mechanisms | Low-dose atropine formulation intended to slow myopia progression. |
| Target Population | Children aged 3–14 years with myopia ranging from –0.50 D to –6.00 D. |
| Care Setting | Clinical trials and regulatory review. |
Key Highlights
- Sydnexis received a complete response letter (CRL) from the FDA for SYD-101.
- The NDA was supported by phase III results from the STAR trial.
- The STAR trial enrolled approximately 847 children with myopia.
- The EMA granted a positive opinion for SYD-101 based on STAR trial data.
- The FDA acknowledged no safety concerns but questioned efficacy.
Guideline-Based Recommendations
Diagnosis
- Assessment of myopia in children aged 3–14 years.
Management
- Consideration of low-dose atropine for myopia progression.
Monitoring & Follow-up
- Regular follow-up on myopia progression rates.
Risks
- Potential lack of efficacy in low-dose atropine treatment.
Patient & Prescribing Data
Children with myopia between –0.50 D and –6.00 D.
SYD-101 is marketed in Europe as Ryjunea®.
Clinical Best Practices
- Engage with regulatory bodies for drug approval processes.
- Monitor treatment outcomes in pediatric populations.
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
